O’Melveny’s Life Sciences CLE Day 2016September 29, 2016 | Life Sciences
O’Melveny’s Life Sciences partners are hosting a Life Sciences CLE Day, complete with panel discussions on hot topics facing life sciences companies and networking opportunities with in-house counsel from pharmaceutical companies on September 29, 2016, in our New York office.
The day’s agenda includes the following topics, as well as a networking breakfast with Judge Faith Hochberg and a panel with O’Melveny partner Ross Galin; Doug Lankler, Executive Vice President and General Counsel of Pfizer; Matt Maletta, Executive Vice President and Chief Legal Officer of Endo Pharmaceuticals; and Allen Waxman, Executive Vice President of Market Access at Eisai Inc.:
- The Supreme Court and Life Sciences: Jon Hacker and Anton Metlitsky
- Cybersecurity: The Board’s Role: Danielle Gray and Jeremy Maltby
- Enforcement Trends and Risk Mitigation Strategies Related to Pharma Distribution Channels: Steve Brody, David Kirman, and Caitlin Bair
- Mass Tort Defense Strategies: Rich Goetz, Amy Laurendeau, and Houman Ehsan
- The New Face of Pharma Patent Litigation: Biosimilars, Brand v. Brand and 505(b)(2): Lisa Pensabene and Dan O’Boyle
- Choosing the Right Medicine: How to Identify and Mitigate Risk in Life Science M&A: Toby Knapp and Rob Ennis
- Emerging Trends in State AG Litigation: Charlie Lifland and Carolyn Kubota
- FDA Perspectives on Use of Social Media in Product Promotion: Seth Ray
- The Role of the Constitution and Administrative Procedure Act in Post-Grant Patent Proceedings: Filko Prugo and Margaret O’Boyle
- “Product Hopping,” Life Cycle Management, and the Namenda Decision: Ted Hassi and Steve McIntyre
Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.